Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Mayo Clinic Develops First Fully Humanized 3D Bioprinted Skin Model Using CollPlant's Plant-Derived rhCollagen

Author: Benzinga Newsdesk | October 16, 2025 06:07am
  • The bioprinted skin model is designed to serve as an alternative to animal testing for preclinical research.
  • According to a scientific article published in the Archives of Dermatological Research, the model developed by Mayo Clinic researchers combines CollPlant's plant-derived recombinant human collagen (rhCollagen) with distinct and essential human skin cell types.
  • This innovative platform offers a sustainable and ethical solution for cosmetic and pharmaceutical testing, disease modeling, and drug development.

REHOVOT, Israel, Oct. 16, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary, non-animal recombinant human collagen (rhCollagen), today announced that, according to a scientific article published in the Archives of Dermatological Research, researchers from Mayo Clinic have developed the first fully humanized 3D bioprinted skin model using CollPlant's plant-derived rhCollagen. The model represents an innovative alternative to animal testing for preclinical research, with broad potential applications in cosmetic and pharmaceutical testing, disease modeling, and drug development.

Posted In: CLGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist